ClinicalTrials.gg
CompletedNCT02183610Updated Jul 8, 2014

Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers

A Phase 1 interventional study of [14C] BI 1356 as oral (p.o.) solution and [14C] BI 1356 solution for i.v. infusion in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
30 Years to 60 Years
Sex
Male
01

Study summary

To determine the basic pharmacokinetics of BI 1356 BS, its metabolite CD 1750 XX and radioactivity including excretion mass balance, excretion pathways and metabolism following the intravenous and oral administration of [14C] BI 1356 BS

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs Blood Pressure (BP), Pulse Rate (PR)), 12-lead (ECG), clinical laboratory tests
  • Age >=30 and Age \<=60 years
  • >=18.5 and BMI \<=29.9 kg/m2 (Body Mass Index)
  • Signed and dated written prior to admission to the study in accordance with Good clinical practice (GCP) and the local legislation

Exclusion Criteria:

  • Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
  • Any evidence of a concomitant disease
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  • History of relevant orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of relevant allergy/ (including allergy to drug or its )
  • Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  • Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
  • Participation in another trial with an drug within two months prior to administration or during the trial
  • Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
  • Inability to refrain from smoking during the stay in the trial centre
  • Alcohol abuse (more than 60 g/day)
  • Drug abuse
  • Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
  • Excessive physical activities (within one week prior to administration or during the trial)
  • Any laboratory value outside the reference range that is of clinical relevance
  • Inability to comply with dietary regimen of study centre
  • A marked baseline prolongation of /QTc interval (e.g., repeated demonstration of a QTc interval >450 ms);
  • Male subjects must agree to minimize the risk of female partners becoming pregnant from the dosing day until 3 months after the completion of the study. Acceptable methods of for male volunteers include a vasectomy no less than 3 months prior to dosing, barrier contraception or a medically accepted contraceptive method. For female partners of male volunteers, acceptable methods of contraception include intra-uterine device, tubal ligation, hormonal contraceptive since at least two months and diaphragm with spermicide

Exclusion criteria specific for this study:

  • Veins unsuitable for infusion and blood sampling
  • PR interval >220 ms or QRS interval >120 ms
  • Female gender
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    [14C] BI 1356 as oral (p.o.) solution

    Drug: [14C] BI 1356 as oral (p.o.) solution

  • Experimental
    [14C] BI 1356 solution for i.v. infusion

    Drug: [14C] BI 1356 solution for i.v. infusion

06

What researchers measure

Primary outcomes

  1. Comparison of individual time course profiles of [14C] radioactivity in whole blood, plasma, urine and faeces

    Time frame: before and up to 264 h after drug administration

  2. Comparison of individual time course profiles of BI 1356 BS and its metabolite CD 1750 XX in plasma and urine

    Time frame: before and up to 264 h after drug administration

  3. Rate and extent of excretion mass balance based on the total radioactivity in urine and faeces

    Time frame: prior to and up to 120 h after start of administration

  4. CBlood cell/Cplasma ratio of [14C] -radioactivity

    Time frame: 1:30, 3, 24 and 72 h after drug administration

  5. Measurement of the plasma protein binding of total [14C] radioactivity in human plasma samples ex vivo

    Time frame: 1:30 and 3 hours post drug administration

  6. Cmax (maximum concentration of the analyte(s) in plasma)

    Time frame: before and up to 264 h after drug administration

  7. tmax (time from dosing to the maximum concentration of the analyte(s) in plasma)

    Time frame: before and up to 264 h after drug administration

  8. AUC0-tz (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to the time of the last quantifiable data point)

    Time frame: before and up to 264 h after drug administration

  9. AUC0-infinity (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to infinity)

    Time frame: before and up to 264 h after drug administration

  10. λz (terminal rate constant in plasma)

    Time frame: before and up to 264 h after drug administration

  11. t1/2 (terminal half-life of the analyte(s) in plasma)

    Time frame: before and up to 264 h after drug administration

  12. MRTpo and MRT, respectively (mean residence time of the analyte(s) in the body after p.o. and i.v. administration)

    Time frame: before and up to 264 h after drug administration

  13. CL/F (apparent/total clearance of the analyte(s) in plasma following extravascular and intravenous administration)

    Time frame: before and up to 264 h after drug administration

  14. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular or intravenous administration (F=1) respectively)

    Time frame: before and up to 264 h after drug administration

  15. feurine,0-tz (amount of analyte excreted in urine within the time interval zero to tz (=120 h) in % of dose)

    Time frame: prior to and up to 120 h after start of administration

  16. fefaeces,0-tz (amount of analyte excreted in faeces within the time interval zero to tz (=120 h) in % of dose)

    Time frame: up to 120 h after drug administration

  17. CLR,0-tz (renal clearance of analyte)

    Time frame: prior to and up to 120 h after start of administration

  18. Fa (drug absorption based on radioactivity data)

    Time frame: up to 264 h after drug administration

Secondary outcomes

  1. Number of patients with adverse events

    Time frame: up to 47 days

  2. Global assessment of tolerability by investigator on a 4-point scale

    Time frame: on day 12 during ambulant visit or on day of discharge on day 13, 14 or 15

  3. Evaluation of local tolerability of the infusion by investigator on a 6-point scale

    Time frame: after start of infusion up to day 15

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006 and a primary completion of Sep 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2014
First posted
Jul 8, 2014
Start
Jul 2006
Primary completionActual
Sep 2006
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02183610
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Jul 2006
Primary completion
Sep 2006
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion